Assembly Biosciences (ASMB) vs BlossomHill Therapeutics (BLSM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BlossomHill Therapeutics is the larger company by market cap ($461.2 million vs $454.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | BLSM |
|---|---|---|
| Share price | $22.19 | $14.51 |
| Market cap | $454.39M | $461.20M |
| 1-day change | -1.38% | +0.69% |
| YTD return | -34.75% | — |
| 1-year return | -42.36% | — |
| 5-year return | -21.31% | — |
| P/E ratio (TTM) | 29.59 | — |
| EPS (TTM) | $0.75 | $-10.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.30M | — |
| Revenue growth (YoY) | +153.52% | — |
| Net income (latest FY) | $-6.12M | — |
| Operating margin | -16.76% | — |
| Net margin | -8.47% | — |
| 52-week high | $39.65 | $27.99 |
| 52-week low | $19.20 | $11.02 |
| Distance from 52-week high | -44.04% | -48.16% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +130.73% | +143.97% |
| Average volume | 309.38K | 193.15K |
| Shares outstanding | 20.48M | 31.78M |
| Employees | 73 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
ASMB vs BLSM FAQ
Which is bigger, Assembly Biosciences or BlossomHill Therapeutics?
BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $461.20M compared with $454.39M for Assembly Biosciences (ASMB).
Are Assembly Biosciences and BlossomHill Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.